Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Share News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Thursday broker round-up UPDATE

Thu, 06th Jun 2013 07:37
Aggreko: Goldman Sachs cuts target price from 2425p to 2125p, while retaining its buy recommendation.Alliance Pharma: FinnCap shifts target price from 35p to 38.50p and stays with its hold recommendation.APR Energy: Goldman Sachs reduces target price from 990p to 945p keeping a buy recommendation.BT Group: Liberum Capital ups target price from 315p to 345p and reiterates a buy recommendation.Daily Mail & General Trust: Numis takes target price from 910p to 1007p maintaining its buy recommendation.European Islamic Investment Bank: Westhouse Securities initiates with a target price of 7p and a buy recommendation.Great Portland Group: Espirito Santo upgrades to buy with a target price of 603p.Go-Ahead Group: Morgan Stanley increases target price from 1355p to 1475p and reiterates an equal-weight rating.G4S: UBS reduces target price from 280p to 240p keeping a neutral rating.Invensys: Morgan Stanley raises target price from 390p to 440p keeping an overweight rating. Citi ups target price from 355p to 400p and maintains a neutral rating.Johnson Matthey: Bank of America increases target price from 2400p to 2950p and upgrades from neutral to buy.Journey Group: WH Ireland shifts target price from 172.50p to 175p and maintains its buy recommendation.Man Group: Bank of America reduces target price from 170p to 130p, while retaining a buy recommendation.Optos: Investec cuts target price from 157p to 124p, while upgrading from sell to reduce.Restaurant Group: Jefferies raises target price from 500p to 575p keeping a buy recommendation.RPC Group: JP Morgan shifts target price from 491p to 496p and stays with its overweight rating.RSA Insurance Group: Morgan Stanley moves target price from 124p to 136p upgrading to overweight.Synergy Health: Canaccord Genuity ups target price from 893p to 902p, but still recommends selling.Thomas Cook Group: UBS lowers target price from 147p to 145p maintaining its neutral rating.Tribal Group: Canaccord Genuity takes target price from 180p to 200p keeping a buy recommendation.Wolseley: Goldman Sachs reduces target price from 3750p to 3600p leaving its neutral rating unchanged.WPP Group: JP Morgan increases target price from 1282p to 1353p and reiterates an overweight rating.Zattikka: Canaccord Genuity cuts target price from 110p to 90p, while leaving its speculative buy recommendation unchanged.

Related News

LONDON MARKET CLOSE: Miners peg back FTSE 100 while mid-caps struggle
13 hours ago

LONDON MARKET CLOSE: Miners peg back FTSE 100 while mid-caps struggle

(Alliance News) - The FTSE 100 edged lower on Tuesday held back by weak miners, while fresh US tech falls and soft UK economic data added to the muted...

WINNERS & LOSERS: easyJet rebuffs third "opportunistic" Castlelake bid
1 day ago

WINNERS & LOSERS: easyJet rebuffs third "opportunistic" Castlelake bid

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Monday.

Amazon Web Services teams with WPP subsidiary on agentic AI use
5 days ago

Amazon Web Services teams with WPP subsidiary on agentic AI use

(Alliance News) - Amazon.com Inc subsidiary Amazon Web Services on Thursday said it has signed a strategic collaboration agreement with WPP Enterprise...

Alliance Pharma News

Alliance Pharma loss narrows in 2024 due to reduced impairment charges
8 Apr 2025

Alliance Pharma loss narrows in 2024 due to reduced impairment charges

(Alliance News) - Alliance Pharma PLC on Tuesday reported a narrowed loss for 2024 despite a decline in revenue, due to a reduction in impairment char...

Alliance Pharma confident despite softer sales
8 Apr 2025

Alliance Pharma confident despite softer sales

(Sharecast News) - Alliance Pharma posted weaker full-year revenues on Tuesday, but insisted it remained well-positioned for medium-term growth.

Alliance Pharma board backs final GBP362 million takeover bid
10 Mar 2025

Alliance Pharma board backs final GBP362 million takeover bid

(Alliance News) - Alliance Pharma PLC on Monday said it has agreed to a final increased cash offer of 64.75 pence per share from Dbay Advisors Ltd and...

Alliance Pharma agrees to take-private deal
10 Mar 2025

Alliance Pharma agrees to take-private deal

(Sharecast News) - Speciality drugmaker Alliance Pharma has agreed to be taken private in a deal valued at more than £360.0m.

Alliance Pharma expects to post flat annual profit, revenue decline
31 Jan 2025

Alliance Pharma expects to post flat annual profit, revenue decline

(Alliance News) - Alliance Pharma PLC on Friday said it expects to report 2024 profit broadly in line with the year before, despite a decline in annua...

LONDON BROKER RATINGS: Jefferies likes Volex; UBS raises Next
31 Jan 2025

LONDON BROKER RATINGS: Jefferies likes Volex; UBS raises Next

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: